Ryugo Teranishi, Tsuyoshi Takahashi, Toshirou Nishida, Yukinori Kurokawa, Kiyokazu Nakajima, Masahiro Koh, Takahiko Nishigaki, Takuro Saito, Kazuyoshi Yamamoto, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Masaaki Motoori, Takeshi Omori, Seiichi Hirota, Yoshito Hayashi, Tetsuo Takehara, Hidetoshi Eguchi, Yuichiro Doki
BACKGROUND: Imatinib mesylate (IM) is the standard chemotherapy for patients with gastrointestinal stromal tumors (GISTs) and has a favorable safety profile. Pharmacokinetics (PK), such as plasma trough concentration (Cmin), varies among patients, requiring the need for therapeutic drug monitoring (TDM) during IM administration. Despite some reports from overseas, the relationship between Cmin, adverse events (AEs), and treatment efficacy in Japanese patients with GIST has still been lacking...
March 27, 2023: International Journal of Clinical Oncology